Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Buspirone Hydrochloride Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01843205
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
Methamphetamine, Placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Results available

Buspirone Treatment for Marijuana Dependence

NCT00875836
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 4, 2026, 5:29 AM EDT
Recruiting Phase 4 Interventional

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

NCT04400266
View directory record Official record
Conditions
Depression, Brain Injuries, Traumatic
Interventions
Buspirone, Mealatonin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 5:29 AM EDT
Active, not recruiting Phase 2 Interventional

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

NCT04458324
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone Hydrochloride, Buspirone placebo, Noninvasive Ventilation (NIV), Sham Non-invasive ventilation (NIV), Functional Electrical Stimulation Row Training (FESRT)
Drug · Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 4, 2026, 5:29 AM EDT
Recruiting Phase 2 Interventional

Evaluating Buspirone to Treat Opioid Withdrawal

NCT05511909
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
Interventions
Buspirone, Lofexidine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

NCT02458469
View directory record Official record
Conditions
Spinal Cord Injury, Sleep Disordered Breathing
Interventions
Buspirone, Trazodone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence

NCT00360191
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Buspirone, Motivational enhancement therapy
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Results available

Buspirone Treatment of Anxiety in Williams Syndrome

NCT04807517
View directory record Official record
Conditions
Williams Syndrome, Anxiety
Interventions
Buspirone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buspirone Hydrochloride 30mg Tablets, Fasting

NCT00840606
View directory record Official record
Conditions
Healthy
Interventions
BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 1 Interventional

Buspirone for Opioid Tapering

NCT03521960
View directory record Official record
Conditions
Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
Interventions
Buspirone oral capsule, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

NCT01641159
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Results available

Improving Driving in Young People With Autism Spectrum Disorders

NCT03538431
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Buspirone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 24 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional

Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy

NCT00166621
View directory record Official record
Conditions
Autism
Interventions
Buspirone
Drug
Lead sponsor
Chugani, Diane C.
Individual
Eligibility
2 Years to 6 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 1 Interventional

Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

NCT00270959
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 4, 2026, 5:29 AM EDT
Terminated Phase 3 Interventional Results available

Buspirone as a Potential Treatment for Recurrent Central Apnea

NCT00746954
View directory record Official record
Conditions
Central Apnea, Heart Failure
Interventions
Acetazolamide, Buspirone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 4, 2026, 5:29 AM EDT
Terminated Phase 1 Interventional

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

NCT02589340
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

NCT00705003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

NCT00174226
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Buspirone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2008 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buspirone Hydrochloride 30mg Tablets, Non-Fasting

NCT00840398
View directory record Official record
Conditions
Healthy
Interventions
BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

NCT01639157
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Buspirone for Early Satiety and Symptoms of Gastroparesis

NCT03587142
View directory record Official record
Conditions
Gastroparesis
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 4, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Results available

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

NCT01821690
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 4, 2026, 5:29 AM EDT